HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target

Pacira Biosciences, Inc.

Pacira Biosciences, Inc.

PCRX

0.00

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ: PCRX) with a Buy and maintains $38 price target.